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Received October 14, 2013; accepted October 28, 2013AbstractAntituberculosis drug-induced liver injury (ATDILI) is the most prevalent hepatotoxicity in many countries. All of the three first-line
antituberculosis drugs, isoniazid, rifampicin, and pyrazinamide, may induce hepatic damage, especially isoniazid. The major drug-
metabolizing enzyme of isoniazid is N-acetyltransferase (NAT). Other possible enzymes are CYP2E1, glutathione S-transferase (GST) and
manganese superoxide dismutase (MnSOD, SOD2). There is evidence that variations of the genes that encode these enzymes may influence the
activity of the corresponding drug-metabolizing enzymes. Recent studies have demonstrated that these genetic variations may be associated with
the risk of ATDILI. Among them, NAT acetylation status has been most studied. The proposed risk-associated genotypes are NAT2 slow
acetylator (without wild-type NAT2*4 allele), CYP2E1 *1A/*1A (homozygous wild type), homozygous null GSTM1 genotype and MnSOD
mutant C allele. Although the available data in the field are complex and inconsistent, meta-analyses disclosed that NAT2 slow acetylator status
possesses the highest association (odds ratio ¼ 3.18). There are associations of CYP2E1 *1A/*1A and homozygous null GSTM1 genotype with
ATDILI by meta-analyses, but the odds ratios were lower than that of NAT2. Of note, there was an ethnic difference in this association. The
ATDILI in East Asians seems to have a higher correlation with genetic variations of NAT2, CYP2E1 and GSTM1. However, the meta-analyses
could not validate these associations in Caucasians, although some showed positive correlations. To mitigate the crucial ATDILI, this review
article underlines the importance of this pharmacogenetic endeavor to identify high-risk patients.
Copyright  2014 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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tuberculosis1. Introduction
Owing to the increasing prevalence of drug-resistant
mycobacterium tuberculosis (TB) strains and patients with
acquired immunodeficiency syndrome (AIDS), TB has been a
growing public health burden and challenge. The three com-
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http://dx.doi.org/10.1016/j.jcma.2014.01.010pyrazinamide, which have the potential to induce liver dam-
age.1 This antituberculosis drug-induced liver injury (ATDILI)
ranges from mild to severe forms, and can even be fatal. The
incidence of ATDILI depends on different antituberculosis
regimens, definitions of liver injury, and ethnic populations.
Generally, 10e20% of patients may have elevation of serum
aminotransferase during administration of these drugs.
Approximately 1% of patients may develop overt hepatitis,
defined as symptomatic hepatotoxicity with jaundice, and
significant elevation of serum aminotransferase.1 The mortal-
ity rate of patients with overt hepatitis is estimated to be
around 10%. ATDILI is the most prevalent drug-induced
hepatotoxicity in Taiwan, China, South Africa and many
other areas, which may both threaten patients’ health andhinese Medical Association. All rights reserved.
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potentially grave drug-induced liver injury (DILI) are crucial.
2. Characteristics of antituberculosis drug-induced liver
injury
Among the antituberculosis drugs, isoniazid is the drug
which most frequently induces hepatotoxicity.1 The latent
period of ATDILI ranges from 1 week to 12 months, with the
median being around 8 weeks.1 The clinical course may be
insidious, without significant symptoms or signs. However,
some cases may have nonspecific manifestations, such as
anorexia, nausea, vomiting, poor appetite, upper abdominal
discomfort, yellowish discoloration of skin and tea-colored
urine. Liver tests often revealed typical hepatocellular
pattern, with elevated serum aminotransferase levels, but with
normal or near-normal serum alkaline phosphatase. Pathology
of the liver is characterized by zonal, submassive, or massive
necrosis in the hepatic lobules. Recovery usually occurs if
drugs are withdrawn before severe liver injury happens. Of
note, liver function may resume to normal in some patients
with mild liver injury, even though the anti-TB drugs are
continuously administered. This is believed to be an “adap-
tation” of the liver to dispose of the drugs and metabolites
more efficiently.1 Metabolic intermediates of isoniazid are
incriminated in induction of liver injury (Fig. 1).2 The
immunological reaction may play a small role in ATDILI.
Rifampicin may induce hepatocellular type liver damage as
isoniazid.1 However, it may also interfere with the uptake and
excretion of bilirubin and cause isolated direct or indirect
hyperbilirubinemia, without elevation of serum aminotrans-
ferase. In addition, rifampicin may augment the activities of
amidase and CYP2E1, and enhance the hepatotoxicity of
isoniazid (Fig. 1).2
Pyrazinamide is known as a dose-dependent hepatotoxin
and causes hepatocellular injury like isoniazid.1 However,
little is known about the risk factors and genetic predisposition
of pyrazinamide or rifampicin-induced liver injury, becauseFig. 1. The metabolic pathway of isoniazid. Isoniazid is first metabolized to acety
drazine by amidase. Acetylhydrazine can be oxidized to many hepatotoxic inter
metabolic pathway to generate toxic metabolites is the direct hydrolysis of isonia
amidase and CYP2E1, and enhance the hepatotoxicity of isoniazid. CYP ¼ cytocmost studies were undertaken with the combination therapy of
anti-TB agents.
3. Risk factors of antituberculosis drug-induced liver
injury
A better understanding of the risk factors and mechanisms
of ATDILI may help us to prevent and mitigate this important
adverse drug reaction. Elderly, female, African American,
Asian, malnutrition, low body weight, alcoholism, pre-existing
liver disease, chronic hepatitis B and C infections, AIDS,
pregnancy, co-administration of hepatotoxic agents, abnormal
baseline liver function and genetic factors have been reported
to increase the risk of ATDILI.1 Pharmacogenetic or phar-
macogenomic approaches to the genetic variations of drug-
metabolizing enzymes (DMEs) and immunological reaction
have recently gained global attention.2 Variations of the
encoding genes may influence the activity of the correspond-
ing DMEs, and then increase or decrease the susceptibility to
ATDILI. Although there have been many reports from
different ethnic populations in this field in the past decade,
most were small in sample size, and with different definition
of DILI.2 Therefore, the results are intricate and complex, and
should be interpreted with caution. Owing to many pharma-
cogenetic meta-analyses in recent years, we have the chance to
re-evaluate the association of genetic factors and ATDILI
more objectively.
4. Genetic variation and susceptibility to ATDILI4.1. N-acetyltransferaseIsoniazid is first metabolized to acetylisoniazid via N-ace-
tyltransferase (NAT), followed by hydrolysis to acetylhy-
drazine (Fig. 1).3 Acetylhydrazine can be oxidized to many
hepatotoxic intermediates by cytochrome P450 2E1
(CYP2E1)4 or acetylated to nontoxic diacetylhydrazine.
Another metabolic pathway to generate toxic metabolites islisoniazid via N-acetyltransferase (NAT), followed by hydrolysis to acetylhy-
mediates by CYP2E1, or acetylated to nontoxic diacetylhydrazine. Another
zid to toxic hydrazine via amidase. Rifampicin may augment the activities of
hrome; NAT ¼ N-acetyltransferase; RIF ¼ rifampicin.
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via amidase.2
It is speculated that the activity of NAT may affect the
detoxification process, and is associated with the susceptibility
to ATDILI. People are identified as rapid or slow acetylators,
according to the activity of NAT. Mitchell et al5 first pointed
out that rapid acetylators were more vulnerable to ATDILI,
because they produced more hepatotoxins via rapid activity of
NAT. However, the disposal of acetylhydrazine also depends
on further acetylation by NAT to form the nontoxic metabolite,
diacetylhydrazine. This crucial detoxification pathway is
slower in slow acetylators, which suggests that slow acetyla-
tors have a higher risk of ATDILI than rapid acetylators in
other studies. Whether rapid or slow acetylator status is related
to the risk of ATDILI has been debated for many decades.
Acetylator status was determined by measuring metabolites of
an index drug catalyzed by NAT in all studies before 2000.
This indirect phenotyping method may be influenced by many
individual intrinsic factors and has bias. Genotyping NAT2 is
believed to be a more accurate method to differentiate rapid
from slow acetylators.
NAT is encoded by NAT1 and NAT2 genes. The latter is the
main human gene controlling hepatic NAT. Humans have
genetic variation in NAT2, which has been proven to influ-
ence the activity of NAT. The NAT2*4 is the wild-type allele,
which possesses the highest NAT activity compared with the
variants (NAT2*5, NAT*6, NAT*7, etc.).3 Accordingly, the
presence of any two variant alleles defines the slow acetylator
phenotype; one variant and one wild-type allele, intermediate
acetylator; and two wild-type alleles, rapid acetylators. Many
researchers merge the intermediate acetylators and rapid
acetylators, and simply divide humans into rapid and slow
acetylators.
By the application of genotyping methods, slow acetylators
were found to have a higher risk of ATDILI than rapid ace-
tylators in recent studies from East Asia.3,4,6e8 Furthermore,
slow acetylators may have more serious liver damage than
rapid acetylators in patients with ATDILI.3 Most studies in
Asia and India show similar findings.6e10 However, some
discordant results came from studies of Caucasians.10,11
Meta-analyses recruiting recent relevant studies revealed
that NAT2 slow acetylators had a higher risk of ATDILI across
different ethnic populations [odds ratio (OR) ¼ 3.18 in total,
Table 1].10,11 However, East Asians had a higher OR than that
of Indians (3.32 vs. 2.96).10 Although some studies of Cau-
casians possessed a statistically significant association of
NAT2 and ATDILI, the meta-analysis failed to establish this
association in Caucasians (Table 1).104.2. Cytochrome P450 2E1CYP2E1, a phase 1 enzyme, is involved in the metabolism
of many carcinogens and drugs, and is associated with sus-
ceptibilities to alcoholic liver disease, nonalcoholic fatty liver
disease and many cancers, such as hepatocellular carcinoma.4
This enzyme also has functional genetic variation in humans.
Three restriction enzymes, RsaI, PstI and DraI, are commonlyused to detect CYP2E1 restriction fragment length poly-
morphism (RFLP). The RsaI and PstI restriction sites are in
the transcription regulation region of CYP2E1, which has been
linked to gene expression.4
The three genotypes of CYP2E1 are classified as c1/c1, c1/
c2 and c2/c2 by RFLP using RsaI as the restriction enzyme.
The wild-type allele is c1 and the variant allele is c2. Ac-
cording to the new nomenclature for CYP2E1, *1A is equiv-
alent to c1 and *5 is equivalent to c2.
Huang et al4 first demonstrated that patients with homo-
zygous wild genotype CYP2E1 *1A/*1A had a higher risk of
hepatotoxicity (OR ¼ 2.52) than those with mutant allele *5
(CYP2E1 *1A/*5 or *5/*5).4 If CYP2E1 *1A/*5 or *5/*5 ge-
notype combined with rapid acetylator status was regarded as
the reference group, the OR of ATDILI increased from 3.94
for CYP2E1*1A/*1A with rapid acetylator status, to 7.43 for
CYP2E1 *1A/*1A with slow acetylator status. Furthermore,
under the administration of isoniazid, individuals with
CYP2E1 *1A/*1A genotype had higher CYP2E1 activity than
those with other genotypes and, hence, may produce more
hepatotoxins and increase the risk of ATDILI.
Some studies from East Asia and Europe support the
aforementioned study,10e13 but others disproved it.14 Recent
meta-analyses disclosed that the CYP2E1 RsaI genetic varia-
tion was associated with the susceptibility to ATDILI in East
Asians, although the OR was not high (OR ¼ 1.35, Table
1).10,12 However, the meta-analyses could not endorse this
association in Indians and Caucasians.10,124.3. Glutathione S-transferaseGlutathione S-transferase (GST), an important phase 2
detoxification enzyme, can catalyze the conjugation of gluta-
thione to a host of electrophils, including arene oxides, un-
saturated carbonyls, organic halides and many other
chemicals.15 The GST supergene family encodes this enzyme
and has functional genetic variations, which are correlated
with the susceptibility of alcoholic liver disease and many
cancers. Individuals with the homozygous “null” mutant ge-
notype of GSTM1 or GSTT1 have been found to lose enzy-
matic activity.
It is reasonable to speculate that individuals with null
GSTM1 or GSTT1 genotypes may have a higher risk of
ATDILI. Roy et al16 first reported that GSTM1 null mutation is
associated with the susceptibility of this DILI, but GSTT1 null
mutation is not. Other studies may or may not support this
finding.15,17,18 Recent meta-analyses demonstrated that the
association of null GSTM1 genotype and ATDILI existed,
although the OR was not high.10,18 Similar to the finding
regarding CYP2E1, the association of GSTM1 null genotype
with ATDILI only existed in East Asians, but not in Indians
and Caucasians.10,18 Further, this association for overall
ethnicity was statistically significant, although it seemed weak
(OR ¼ 1.43, Table 1).10,18
Regarding the other important GST T1 null genotype, only
a few small-scale studies suggest an association with
ATDILI. The results of recent meta-analyses disproved the
Table 1
Odds ratios of antituberculosis drug-induced liver injury associated with proposed high-risk genetic variations in different ethnic populations.
Genetic variations Overall East Asian Indian Caucasian References
Drug-metabolizing enzyme
dNAT2 slow acetylator 3.18a,* 3.32a,* 2.96a,* 1.44a 3e11
dCYP2E1 *1A/*1A 1.28a 1.35a,* 0.56a 0.81a 4,6e8,10,
12e14
dGSTM1 null 1.43a,* 1.55a,* 1.70a 0.73a 10,15e18
dGSTT1 null 1.07a 0.96a 2.92a 2.60a 10,15e18
dMnSOD (SOD2) variant c1 allele d 2.47* d d 15
dUGT1A1 variant*27, *28 allele d 13.86* d d 19
dNOS2 C/C d 3.60* d d 20
dBACH1 C/C d 29.14* d d 20
dMAFK G/A, A/A d 5.72* d d 20
Immunological reaction
dHLA-DQB1*0201 d d 1.90* d 21
dTNF-a -308 variant A allele d 1.95* d d 22
*p < 0.05.
BACH ¼ BTB and CNC homology 1; CYP ¼ cytochrome P450; GST ¼ glutathione S-transferase; HLA ¼ human leukocyte antigen; MAFK ¼Maf basic leucine
zipper protein; MnSOD¼manganese superoxide dismutase; NAT ¼ N-acetyltransferase; NOS ¼ nitric oxide synthase; TNF ¼ tumor necrosis factor; UGT ¼ UDP
glucuronosyltransferase.
a Data derived from meta-analyses.
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(Table 1).10,184.4. Manganese superoxide dismutaseManganese superoxide dismutase (MnSOD, SOD2) is a
crucial phase 2 enzyme with an antioxidative property.15 A
thymine (T)-to-cytosine (C) substitution at position 47 in the
human MnSOD gene was found, resulting in an alanine-for-
valine substitution in the leader amino acid sequence.15 In
turn, this amino acid substitution may modify the helical
structure of the mitochondrial targeting sequence, and then
augment the import of MnSOD into the mitochondrial matrix.
This T/C genetic variation has been associated with an
increased risk of many cancers and alcoholic liver disease.15
Huang et al15 found that individuals with a variant C allele
(T/C or C/C genotype) ofMnSOD had a higher risk of ATDILI
than did those with MnSOD T/T genotype (OR ¼ 2.47, 95%
confidence interval ¼ 1.13e5.39, p ¼ 0.02). However, this
study warrants further research to verify these findings.4.5. UDP glucuronosyltransferaseUDP glucuronosyltransferase (UGT), an important phase 2
enzyme group, is associated with the conjugation and
detoxification of many drugs, xenobiotics and bilirubin.19
Genetic variations of UGT are associated with drug-induced
hyperbilirubinemia, Gilbert’s syndrome and many cancers.
One report from Taiwan disclosed that individuals with
both UGT1A1 variant*27 and *28 alleles had a very high
OR for ATDILI (OR ¼ 13.86, 95% confidence
interval ¼ 1.09e177.04, p ¼ 0.043).19 However, the case
number was limited in this study. Further studies with a large
sample size and with different ethnic populations are war-
ranted to clarify the role of UGT genetic variation in the risk of
ATDILI.4.6. Antioxidant pathway proteinsThe antioxidation pathway is critical to detoxify many free
radicals and toxic chemicals. Many enzymes and transcription
factors are involved in this pathway to regulate the antioxidative
process. Similarly, genetic variations of the associated regula-
tory genes may confer different activities on the relevant en-
zymes.Nitric oxide synthase (NOS), BTB andCNChomology 1
(BACH) and Maf basic leucine zipper protein (MAFK) are
important antioxidant enzymes or transcription factors. One
recent study from Japan disclosed that a C/C genotype at
rs11080344 in NOS2A, a C/C genotype at rs2070401 in BACH1
and a G/A or A/A genotype at rs4720833 in MAFK indepen-
dently conferred ATDILI susceptibility with a very high OR
(Table 1).20 However, the sample size of ATDILI cases in this
studywas very small (n¼ 18).20 The association of genotypes of
these antioxidant proteins and ATDILI needs large-scale
research for confirmation.4.7. Human leukocyte antigenAlthough it is generally believed that genetic variations of
DMEs comprise the major pathogenesis of ATDILI, immu-
nological reactions still play some role in this hepatotoxici-
ty.21,22 Among the immunological reaction, human leukocyte
antigen (HLA) variation has been well explored in many dis-
eases. Only one available study from India has shown that
HLA-DQB1*0201 genotype is associated with ATDILI.21
Owing to HLA variation in different ethnic populations, the
association of HLA and ATDILI awaits further confirmation.
5. Conclusion
From the available data and meta-analyses, the possible
high-risk genetic variations are NAT2 slow acetylator (without
wild-type NAT2*4 allele), CYP2E1 *1A/*1A (homozygous
173Y.-S. Huang / Journal of the Chinese Medical Association 77 (2014) 169e173wild type), homozygous null GSTM1 genotype and MnSOD
mutant C allele. Among them, NAT2 slow acetylator status
possesses the highest association. The correlation of CYP2E1
and GSTM1 genotype with ATDILI is low. Of note, ethnic
differences exist in this association. ATDILI in East Asians
seems to have a significant correlation with genetic variations
of NAT2, CYP2E1 and GST M1. However, the meta-analysis
could not validate these associations in Caucasians, although
some studies showed positive correlations.
It is suggested that patients with high-risk genotypes should
have regular liver biochemical tests in the first few months
following administration of antituberculosis drugs. Tailoring
the antituberculosis regimen to patients according to individ-
ual genetic profiles is expected in the near future.23
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